We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Omega Diagnostics Group Plc | LSE:ODX | London | Ordinary Share | GB00B1VCP282 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.20 | 2.00 | 2.40 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/7/2018 18:51 | Could it not be the stake held by Soc Gen Private Banking ? Their stake has been declining slowly from 4% over a year ago . | bomber13 | |
30/7/2018 18:18 | Holding RNS - I didn't know that Alto Invest (France)had a holding over 3% in the first place..... | barrywhit | |
25/7/2018 11:22 | lots of sells in the last week or two, mm's have been happy to take them, hence my post 844.......some one taking a stake??? or Sneller??? | barrywhit | |
25/7/2018 09:19 | A couple of very large trades at 15p this morning! | hyperboreus | |
25/7/2018 07:43 | Could do with Elton on the board! Link to the distributor for VISITECT CD4 in Zimbabwe and Zambia, not sure who ODX are intending to use in Nigeria & Ghana respectively once production registration process is complete: | hyperboreus | |
24/7/2018 11:28 | weatherman, thanks for the link.... | barrywhit | |
23/7/2018 12:49 | They must be filling an order .... | barrywhit | |
19/7/2018 16:45 | To be honest, I expect to see further news on other parts of the business before results. Note the wordings on the NOTICE OF RESULTS RNS: "Further to the disposal of our infectious disease business (excluding VISITECT® CD4), which we announced on 28 June 2018, the extended timeline for releasing results will enable the Company to prioritise its stated objectives." The above is open to interpretation but I am of the opinion there will be further news before results, which will then be discussed further during the presentation. | jeevsje | |
19/7/2018 15:49 | Yep, fair point. | tickboo | |
19/7/2018 15:09 | tickboo - he won't be able to tell investors anything they don't already know and suspect mainly preaching to the converted. The game changing news will be WHO prequisite go ahead and thats not due until late this year/early next year. | dibs61 | |
19/7/2018 10:42 | I think they'll be more interest after the investor presentation. The CEO is clearly keen to create that elusive shareholder value and I'm sure will do a good job selling their strategy and vision. | tickboo | |
18/7/2018 20:45 | Mainly sells today, last year that RNS would have sent the share price 2p higher, now we have no P.I's so a few traders taking a profit..... | barrywhit | |
18/7/2018 09:22 | are the trades at 15.85p sells???? | barrywhit | |
18/7/2018 09:03 | Thanks chaps! The RNS for these things is quite often the same day as the actual event, so I didn't bother to read the full RNS....lesson learnt :o)) Now off to see if I can make the 6th August.... | rivaldo | |
18/7/2018 08:36 | Second one gone through for less. | tickboo | |
18/7/2018 08:25 | Presentation is on 6 August rivaldo after the full year results! | hyperboreus | |
18/7/2018 08:24 | Rivaldo, the event is on the 06th of August. | jeevsje | |
18/7/2018 08:20 | Good to see more indications that CD4 is finally coming to fruition. Did anyone go to the 12th July presentation ( I was on hols)? | rivaldo | |
18/7/2018 08:11 | Buy order being filled at 16p, hence why no buy quotes online. Will move up sharply during the day, esp with lack of sellers. | jeevsje | |
18/7/2018 07:48 | More progress, he seems to mention shareholder value at every opportunity which is good to read, heading in the right direction.... | barrywhit | |
18/7/2018 07:10 | Back to 20s. News on other deals yet to come. | jeevsje | |
16/7/2018 22:09 | Ready to drop again? | jeevsje |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions